These findings are consistent with a model whereby a reduction of the AHR pathway, either via reducing Ahr expression (as in our mouse model), or increased AHRR expression in human tumours, is associated with more aggressive SHH medulloblastoma tumours and reduced patient survival. This evidence concerns the gene AHRR and neoplasm.